The FDA is opening the door for feedback on a new contractual framework aimed at establishing direct working relationships with qualified venture capital firms. This shift signals a growing recognition of the need for closer collaboration between regulatory bodies and the investment community. The proposed model could reshape how innovation gets funded and vetted, particularly in sectors where rapid technological advancement outpaces traditional approval timelines. Industry watchers are keen to see how this unfolds and what it means for early-stage projects seeking regulatory clarity.